Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks?

With a market cap of $115.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a leading biotechnology firm based in Boston, best known for its dominance in cystic fibrosis treatments through drugs like Trikafta.

Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Vertex Pharmaceuticals fits this criterion perfectly. Its market dominance, innovative pipeline, and financial resilience make it a leading player in the biotechnology industry. The company is also a pioneer in advanced therapies, including gene-editing (Casgevy) and non-opioid pain management (JOURNAVX). 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.